Diabetic Nephropathy Market to Gain from Increasing Patient Burden and New Drug Launches; Growing at a 6.5% CAGR During the Study Period [2018-2030], Evaluates DelveInsight
The Diabetic Nephropathy pipeline is promising, consisting of various assets such as Jardiance (Boehringer & Eli Lilly), Bardoxolone methyl (Kyowa Kirin), TMX-049 (Teijin America), and others, which are in late stages of clinical development
LAS VEGAS, Sept. 7, 2021 /PRNewswire/ -- DelveInsight's "Diabetic Nephropathy Market" report provides a thorough comprehension of the Diabetic Nephropathy historical and forecasted epidemiology and the Diabetic Nephropathy market trends in the 7MM [the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan]. The Diabetic Nephropathy market report also proffers an analysis of the current Diabetic Nephropathy treatment algorithm/practice, market drivers, market barriers, and unmet medical needs.
Some of the necessary takeaways from the Diabetic Nephropathy Market Research Report
- Several key pharmaceutical companies, including Bayer, Janssen Pharmaceutical, AstraZeneca, Daiichi Sankyo, Teijin America, Boehringer Ingelheim, Eli Lilly and Company, Chinook Therapeutics, Abbvie, Mitsubishi Tanabe Pharma, CSL Behring, Gilead Sciences, Goldfinch Bio, Novartis Pharmaceuticals, Prokidney, and others, are developing novel products to improve the Diabetic Nephropathy treatment outlook.
- The pipeline for Diabetic Nephropathy is robust, including drugs such as esaxerenone, bardoxolone methyl, TMX-049, and others in different clinical development stages.
- With the recent drug approval, key therapies such as Farxiga, Invokana, and Kerendia have paved the way for future therapies.
- The Diabetic Nephropathy market is to enlarge owing to an increased prevalence of Diabetes and Diabetic Kidney Disease, frequent annual screening programs, multidisciplinary care, and the development of novel biomarkers. However, due to the heterogeneous nature of the disease, lack of awareness among the patients and primary care physicians, poor access to health insurance and healthcare, and treatment challenges will likely hinder the Diabetic Nephropathy market growth size.
For further information on Market Impact by Therapies, visit: Diabetic Nephropathy Drugs Market Analysis
Diabetic Nephropathy, also known as diabetic kidney disease (DKD), is a clinical syndrome that is characterized by continual albuminuria and a progressive lowering in renal function.
DelveInsight estimates that the total Diabetic Nephropathy prevalent cases in 7MM in 2020 were 27,634,000 cases, out of which the highest cases were observed in the United States.
The Diabetic Nephropathy Market Analysis Report provides historical as well as forecasted epidemiological analysis segmented into:
- Diabetic Nephropathy Prevalence
- Age-specific cases of Diabetic Nephropathy
- Gender-specific cases of Diabetic Nephropathy
- Stage-specific cases of Diabetic Nephropathy
Get a complete epidemiological segmentation breakdown @ Diabetic Nephropathy Epidemiological Analysis
Diabetic Nephropathy Treatment Market
The current Diabetic Nephropathy management leaves a substantial residual risk for kidney disease progression, morbidity, and mortality despite all the treatment options. Therefore, novel treatments are being developed that target inflammation, fibrosis, oxidative stress, renal hemodynamics, glomerular hyperfiltration, the endothelin system, Janus kinase (JAK)-signal transducer, and activator of transcription (STAT) pathway, and others.
Among novel treatments, mineralocorticoid receptor antagonists (MRA) are considered extremely promising. The first oral MRA was spironolactone followed by Eplerenone; both are steroidal MRA. These drugs are often used off-label in T2DM patients with mild-to-moderate arterial hypertension and albuminuria. However, the risk of the development of hyperkalemia with their usage remains a pressing issue.
Finerenone is a first-in-class nonsteroidal MRA indicated to reduce the risk of sustained estimated glomerular filtration rate decline, kidney failure, cardiovascular death, nonfatal myocardial infarction, and hospitalization for heart failure. Recently, the FDA has approved finerenone (Kerendia, Bayer) to treat adult patients with CKD associated with T2D. The approval also follows the previously granted priority review designation by the FDA. Bayer has also submitted an application for approval in the EU.
Another recently launched SGLT-2 inhibitor is Farxiga. It was approved for CKD in the US in April 2021 based on a CKD trial that included both diabetics and nondiabetics. Farxiga has been recommended for approval by the Committee for Medicinal Products for Human Use (CHMP) in the EU for CKD treatment in adults with and without T2D. In addition, the drug is under review in Japan.
Diabetic Nephropathy Drugs and Market Dynamics
Treatment of diabetes and CKD is complex; however, the pipeline for Diabetic Nephropathy is promising, consisting of various assets such as esaxerenone (Daiichi Sankyo), bardoxolone methyl (Kyowa Kirin), TMX-049 (Teijin America), and others in different stages of clinical development. With the recent drug approval, essential therapies such as Farxiga, Invokana, and Kerendia have paved the way for future therapies.
The Diabetic Nephropathy market will observe growth since there have been persistent rising disease cases, which will proffer opportunities to companies to launch new therapies. Also, improved understanding of the disease over the past years will allow new targets to improve treatment scenarios. There have been technological advances in diagnostic procedures, and clinical guidelines agreeing on recommended targets and in clinical practice have been issued. Identification of biomarkers for early detection in Diabetic Nephropathy patients will help better manage and prevent their progression. Moreover, personalized medicine is being prescribed to improve renal and cardiovascular protection in diabetic patients with Diabetic Nephropathy.
Nevertheless, the lack of innovative treatment strategies to prevent, arrest, treat and reverse the disease; different clinical presentation and progression rates among individuals make management of Diabetic Nephropathy challenging. Also, the absence of routine screening and the lack of early and accurate risk stratification of Diabetic Kidney Disease (DKD) patients are troublesome. The lack of animal models replicating clinical features of human DKD has raised concerns about the utility of these models in preclinical drug discovery. Poor medication adherence leads to treatment failure, leading to accelerating disease-related complications. For the last two decades, the standard of care for management has been risk-factor control and renin-angiotensin system (RAS) inhibition. And, lack of awareness and limited knowledge among the patients and primary care physicians are noticeable shortcomings, which need to be addressed soon; these all factors are inhibiting the growth of the Diabetic Nephropathy market.
Scope of the Diabetic Nephropathy Market Insight Report
- Geography Covered: The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan.
- Study Period: 3-year historical and 10-year forecasted analysis (2018-2030).
- Diabetic Nephropathy Markets Segmentation: By Geographies and By Diabetic Nephropathy Therapies (Historical and Forecasted, Current and Upcoming)
- Dominant Market Companies investigating its candidates for Diabetic Nephropathy: Bayer, Janssen Pharmaceutical, AstraZeneca, Daiichi Sankyo, Teijin America, Boehringer Ingelheim, Eli Lilly and Company, Chinook Therapeutics, Abbvie, Mitsubishi Tanabe Pharma, CSL Behring, Gilead Sciences, Goldfinch Bio, Novartis Pharmaceuticals, Prokidney, and several others.
- Analysis: Comparative and conjoint analysis of emerging therapies.
- Case Studies
- KOL's Views
- Analyst's View
Request for a Webex demo of the report @ Diabetic Nephropathy Therapeutics Market
Table of Contents
1 | Diabetic Nephropathy Report Introduction |
2 | Diabetic Nephropathy Patient Share at a Glance |
3 | Executive Summary of Diabetic Nephropathy |
4 | Diabetic Nephropathy Disease Background and Overview |
5 | Diabetic Nephropathy Epidemiology and Patient Population |
6 | Country Wise-Epidemiology of Diabetic Nephropathy |
6.1 | The United States |
6.2 | EU5 Countries |
6.2.1 | Germany |
6.2.2 | France |
6.2.3 | Italy |
6.2.4 | Spain |
6.2.5 | The United Kingdom |
6.3 | Japan |
7 | Organizations contributing toward the fight against Diabetic Kidney Disease |
8 | Diabetic Nephropathy Case Reports |
9 | Diabetic Nephropathy Patient Journey |
10 | Diabetic Nephropathy Marketed Therapies |
10.1 | Kerendia (Finerenone): Bayer |
10.2 | INVOKANA (Canagliflozin): Janssen Pharmaceutical |
10.3 | Farxiga (Dapagliflozin): AstraZeneca |
11 | Diabetic Nephropathy Emerging Therapies |
11.1 | Esaxerenone (CS-3150): Daiichi Sankyo |
11.2 | TMX-049: Teijin America |
11.3 | Jardiance (Empagliflozin): Boehringer Ingelheim/Eli Lilly and Company |
12 | Other Assets |
12.1 | Atrasentan: Chinook Therapeutics/Abbvie |
12.2 | Apararenone (MT-3995): Mitsubishi Tanabe Pharma |
12.3 | MEDI3506: AstraZeneca |
12.4 | Cotadutide (MEDI 0382): AstraZeneca |
12.5 | BI 685509: Boehringer Ingelheim |
12.6 | CSL346 (2H10): CSL Behring |
12.7 | Selonsertib (GS-4997): Gilead Sciences |
12.8 | GFB-887: Goldfinch Bio |
12.9 | Nidufexor (LMB-763): Novartis Pharmaceuticals |
12.10 | Renal Autologous Cell Therapy (REACT): Prokidney |
12.11 | AZD5718: AstraZeneca |
12.12 | Verinurad (RDEA-3170): AstraZeneca |
13 | Diabetic Nephropathy 7MM Market Analysis |
13.1 | The United States Diabetic Nephropathy Market Size |
13.2 | EU-5 Diabetic Nephropathy Market Size |
13.2.1 | Germany Market Size |
13.2.2 | France Market Size |
13.2.3 | Italy Market Size |
13.2.4 | Spain Market Size |
13.2.5 | The United Kingdom Market Size |
13.2.3 | Japan Diabetic Nephropathy Market Size |
14 | Diabetic Nephropathy Market Drivers |
15 | Diabetic Nephropathy Market Barriers |
16 | Diabetic Nephropathy SWOT Analysis |
17 | Diabetic Nephropathy Unmet Needs |
18 | Diabetic Nephropathy KOL Views |
19 | Appendix |
20 | DelveInsight Capabilities |
21 | Disclaimer |
22 | About DelveInsight |
Browse full report with detailed TOC with charts, figures, tables @ Diabetic Nephropathy Diagnostics Market Report
View Other Reports
DelveInsight's Diabetic Nephropathy - Epidemiology Forecast 2030 report delivers an in-depth understanding of the disease, historical, and forecasted epidemiology of Diabetic Nephropathy in the United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan.
Diabetic Nephropathy Pipeline Insights, 2021 report by DelveInsight outlines comprehensive insights of present clinical development scenario and growth prospects across the Diabetic Nephropathy market.
DelveInsight's Persistent Corneal Epithelial Defects (PEDs) - Market Insights, Epidemiology, and Market Forecast - 2030 report provides a detailed overview of the disease. Key companies include Dompe Farmaceutici, OcuNexus Therapeutics, Eyevance Pharmaceuticals, Noveome Biotherapeutics, RegeneRx Biopharmaceuticals, Recordati Rare Diseases, Mimetech, and others are developing Persistent Epithelial Defect therapies.
DelveInsight's Hormone Sensitive Advanced Prostate Cancer Market Insights, Epidemiology and Market Forecast - 2030 report provides a detailed overview of the disease.
DelveInsight's Nephroblastoma Market Insights, Epidemiology, and Market Forecast - 2030 report provides a detailed overview of the disease and an in-depth understanding of historical and forecasted epidemiology.
DelveInsight's Nerve Entrapment Syndrome Market Insights, Epidemiology and Market Forecast - 2030 report provides a detailed overview of the disease and an in-depth understanding of historical and forecasted epidemiology.
DelveInsight's Periodontal Disease - Market Insights, Epidemiology and Market Forecast - 2030 report provides a detailed overview of the disease and an in-depth understanding of historical and forecasted epidemiology.
DelveInsight's "Peripheral Arterial Disease (PAD)/ Pulmonary Vascular Disease (PVD) - Market Insights, Epidemiology, and Market Forecast-2030" report delivers an in-depth understanding of the Peripheral Arterial Disease (PAD)/ Pulmonary Vascular Disease (PVD), historical and forecasted epidemiology as well as the Peripheral Arterial Disease (PAD)/ Pulmonary Vascular Disease (PVD) market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.
Browse Blog Posts
- Explore Cost-effectiveness, Advanced Technology, Rising Demand that Pushes the Insulin Delivery Devices Market
- Read FemTech Market: With 100+ Startups in the domain, Women Healthcare is Witnessing a Huge Upliftment
About DelveInsight
DelveInsight is a leading Business Consultant, and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance. It also provides Business Consulting Services with a credible market analysis that will help accelerate the business growth and overcome challenges with a practical approach.
Contact Us:
Shruti Thakur
info@delveinsight.com
+1(919)321-6187
www.delveinsight.com
Logo: https://mma.prnewswire.com/media/1082265/DelveInsight_Logo.jpg
Share this article